Why does lactate dehydrogenase (LDH) increase in a hypertensive emergency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Why LDH Increases in Hypertensive Emergency

Lactate dehydrogenase (LDH) rises in hypertensive emergencies primarily as a marker of thrombotic microangiopathy—a specific form of acute target-organ damage characterized by microangiopathic hemolytic anemia with red blood cell destruction.

Pathophysiologic Mechanism

  • Acute hypertensive microangiopathy develops when severe blood pressure elevation causes endothelial dysfunction and microvascular damage, leading to thrombotic microangiopathy in the kidneys and other organs 1, 2.

  • Mechanical hemolysis occurs as red blood cells are sheared by fibrin strands deposited in damaged small vessels, releasing intracellular LDH into the circulation 3.

  • The renin-angiotensin system becomes markedly activated in malignant hypertension, correlating with the degree of microvascular damage and perpetuating the vicious cycle of endothelial injury 1, 2.

  • Pressure-induced natriuresis leads to volume depletion, which paradoxically further stimulates the renin-angiotensin system and worsens renal vasoconstriction 1, 2.

Diagnostic Significance in Hypertensive Emergency

LDH is specifically measured to detect thrombotic microangiopathy, which is defined as any situation where severe BP elevation coincides with Coombs-negative hemolysis (elevated LDH, unmeasurable haptoglobin, or schistocytes) and thrombocytopenia in the absence of another plausible cause 1.

Essential Laboratory Panel

  • A comprehensive laboratory panel should include hemoglobin, platelets, creatinine, sodium, potassium, LDH, and haptoglobin to assess for thrombotic microangiopathy and guide management 3.

  • Elevated LDH with decreased haptoglobin and thrombocytopenia indicates thrombotic microangiopathy, a specific form of acute target-organ damage requiring emergency intervention 3.

  • LDH measurement has a strength of evidence level B for detecting microangiopathic hemolytic anemia in hypertensive emergencies 3.

LDH as a General Tissue Damage Marker

  • LDH is widely distributed in heart, liver, skeletal muscle, kidney, and erythrocytes; when cells are injured, intracellular LDH is released into plasma, changing the serum isoenzyme pattern to favor the profile of the affected organ 4.

  • In hypertensive patients, LDH levels correlate inversely with endothelial function (measured by flow-mediated dilation), suggesting that elevated LDH reflects ongoing vascular damage beyond just hemolysis 5.

  • Hypertensives with elevated pulmonary artery pressure show markedly increased activities of LDH-M isoenzyme, indirectly reflecting alterations in organ metabolism and hypertension-linked complications 6.

Prognostic Implications

  • Very high isolated LDH (≥800 IU/L) is an independent predictor of mortality in hospitalized medical patients, associated with more admission days, significantly more in-hospital major complications, and a mortality rate of 26.6% versus 4.3% in controls 7.

  • LDH elevation >10-fold the normal rate carries a pejorative prognosis with a mortality rate exceeding 50%, though it does not differentiate benign from malignant etiologies 8.

  • Patients with hypertensive emergencies who develop thrombotic microangiopathy (evidenced by elevated LDH and hemolysis) remain at significantly increased cardiovascular and renal risk even after stabilization 3.

Clinical Application

Do not delay laboratory testing in hypertensive emergency—immediate assessment of LDH, haptoglobin, platelets, and peripheral smear is crucial for identifying thrombotic microangiopathy, which requires specific management considerations 3.

  • Hypertensives with increased LDH need to be screened for target organ damage, including microalbuminuria and endothelial dysfunction, with more frequent follow-up 5.

  • The presence of thrombotic microangiopathy (elevated LDH with hemolysis and thrombocytopenia) should improve during BP-lowering therapy; failure to improve suggests an alternative diagnosis 1.

  • Remember that laboratory findings must be interpreted in clinical context—not all LDH abnormalities are directly related to the hypertensive crisis, as 43 different etiologies can elevate LDH 3, 8.

Related Questions

What are the causes of elevated Lactate Dehydrogenase (LDH) levels?
What is the best course of action for a non-metastatic (non-cancer spread) chemotherapy patient with elevated lactate dehydrogenase (LDH) levels?
What are the causes of elevated lactate dehydrogenase (LDH) levels?
What are the causes of elevated Lactate Dehydrogenase (LDH)?
What are the causes of elevated Lactate Dehydrogenase (LDH) levels?
For a patient with advanced/metastatic leiomyosarcoma who has progressed after first‑line anthracycline (doxorubicin) ± ifosfamide, should trabectedin be given in combination with other agents or as a single agent, and what is the recommended dose?
What is the appropriate management for a 14‑year‑old female with isolated nipple pruritus, no palpable mass, erythema, discharge, or skin changes, occurring only with clothing contact?
What is the recommended management for a patient presenting with atrial fibrillation with rapid ventricular response and hypotension?
What are the Nelson-recommended assessment and empiric therapy guidelines for a child with suspected meningitis?
A 53‑year‑old woman with major depressive disorder and past psychotic features, now worsening depression with suicidal thoughts despite being on Wellbutrin (bupropion) XL 450 mg daily, Lexapro (escitalopram) 20 mg daily, Zyprexa (olanzapine) 5 mg daily, and Klonopin (clonazepam) 0.5 mg three times daily with normal labs—what medication changes should be made?
What breast cancer screening strategy should be used for a 38‑year‑old woman with an estimated lifetime breast cancer risk of 17%?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.